Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Text search

Sort by Name

Click to order products descending

Display 15 Products per page

Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.
July 2, 2018
Find out more
Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.
September 28, 2016
Find out more
Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
Find out more
Company Analysis: Vertex

$3,000.00

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: United Therapeutics

$3,000.00

PharmaVitae explores United Therapeutics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: UCB

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
January 25, 2021
Find out more
Company Analysis: Teva

$3,000.00

PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Takeda

$3,000.00

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.
January 29, 2021
Find out more
Company Analysis: Sumitomo Dainippon

$3,000.00

PharmaVitae explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019–29.
January 28, 2021
Find out more
Company Analysis: Shionogi

$3,000.00

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.
January 29, 2021
Find out more
Company Analysis: Seagen

$3,000.00

PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: Sanofi

$3,000.00

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: Roche

$3,000.00

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Regeneron

$3,000.00

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Pfizer

$3,000.00

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
August 28, 2020
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *